$1.6 Billion Worldwide Transfection Technologies Industry to 2027 – Featuring Lonza, Maxcyte, Mirus Bio and Polyplus Transfection Among Others – Yahoo Finance
DUBLIN, Oct. 10, 2022 /PRNewswire/ — The “Transfection Technologies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering.
The global transfection technologies market size reached US$ 992.8 Million in 2021. Looking forward, the publisher expects the market to reach US$ 1,619.7 Million by 2027, exhibiting a CAGR of 8.5% during 2021-2027.
Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Transfection technology refers to the process of artificially introducing nucleic acid, such as Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA) and oligonucleotides, into the cells. It is introduced using various physical, chemical and biological methods, which can assist in modifying certain properties of the cell.
It involves various methods, including cotransfection, electroporation, cationic lipid transfection and in-vivo transfection. This process is commonly used for various genomic studies that include gene expression, screening, RNA interference and Vivo research, along with the bioproduction of viruses and proteins.
The increasing prevalence of cancer and various chronic lifestyle diseases is one of the key factors driving the growth of the market. Furthermore, widespread adoption of reagent-based methods is also providing a boost to the market growth. In comparison to the traditionally used techniques, reagent-based transfection is less complicated to administer and more cost-effective.
In line with this, instrument-based methods, such as biolistic technology, microinjection and laserfection, are also gaining immense traction across the globe. Various technological advancements in cell research and therapeutic discovery are acting as another major growth-inducing factor.
In line with this, research in gene transfer is majorly performed under in-vivo conditions for the development of novel therapeutic drugs and various other applications. Other factors, including increasing investments by both government and private organizations to develop large scale transfection facilities, along with extensive research and development (R&D) activities in the field of protein therapeutics, are projected to drive the market further.
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Bio-RAD Laboratories Inc., Lonza Group AG, Maxcyte Inc., Mirus Bio LLC, Polyplus Transfection, Promega Corporation, Roche Holding AG, Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., etc.
Key Questions Answered in This Report:
How has the global transfection technologies market performed so far and how will it perform in the coming years?
What are the key regional markets?
What has been the impact of COVID-19 on the global transfection technologies market?
What is the breakup of the market based on the product type?
What is the breakup of the market based on the application?
What is the breakup of the market based on the transfection method?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the end-user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global transfection technologies market and who are the key players?
What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Transfection Technologies Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 Reagent
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Instrument
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Application
7.1 Therapeutic Delivery
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Bio-Medical Research
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Protein Production
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Transfection Method
8.1 Lipofection
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Eletroporation
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Nucleofection
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Cotransfection
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Cationic Lipid Transfection
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 In-Vivo Transfection
8.6.1 Market Trends
8.6.2 Market Forecast
8.7 Others
8.7.1 Market Trends
8.7.2 Market Forecast
9 Market Breakup by Technology
9.1 Physical Transfection
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Biochemical Based Transfection
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Viral-Vector Based Transfection
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by End-User
10.1 Research Centers and Academic Institutes
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Hospitals and Clinics
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Pharmaceutical and Biotechnology Companies
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Others
10.4.1 Market Trends
10.4.2 Market Forecast
11 Market Breakup by Region
12 SWOT Analysis
13 Value Chain Analysis
14 Porters Five Forces Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Agilent Technologies Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Bio-RAD Laboratories Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Lonza Group AG
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Maxcyte Inc.
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.3.3 Financials
15.3.5 Mirus Bio LLC
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.6 Polyplus Transfection
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.7 Promega Corporation
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.8 Roche Holding AG
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.9 Sigma-Aldrich Corporation
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.10 Thermo Fisher Scientific Inc.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/ee41hb
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo:https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/1-6-billion-worldwide-transfection-technologies-industry-to-2027—featuring-lonza-maxcyte-mirus-bio-and-polyplus-transfection-among-others-301644540.html
SOURCE Research and Markets
Billionaire hedge-fund investor Paul Tudor Jones says investors looking to time the bottom in stocks should keep a close eye on short-term Treasury yields.
Shares of enterprise software companies Twilio (NYSE: TWLO), Snowflake (NYSE: SNOW), and Appian (NASDAQ: APPN) fell hard again Monday, down 6.3%, 9.3%, and 6.5%, respectively, as of 3:44 p.m. EDT. In addition, long-term bond yields remained high. On Monday, cloud-based service-center software company Five9 (NASDAQ: FIVN) plunged over 25%, after CEO Rowan Trollope announced he would be resigning for another role at a pre-IPO tech company.
After the annus horribilis of 2022, with the final quarter now in play, investors will be hoping a late-year rally will materialize. According to Carson Group's chief market strategist Ryan Detrick, that’s not such a far-fetched idea. "While October has a reputation for crashes, it is really a bear market killer,” Detrick recently wrote. “Of the past 17 bear (or near bear markets), stocks bottomed in October six times. Could it happen again? With sentiment this pessimistic and extremely positive
In this article, we discuss 5 dividend stocks that are too cheap to ignore. You can skip our detailed analysis of dividend stocks and their returns in the past, and go directly to read 5 Dividend Stocks That Are Too Cheap To Ignore. As the market plunges to its new lows in 2022, investors are […]
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Anyone who held Carnival Corporation…
The company, which is effecting a rare reverse-stock split, is coping with a period of rising interest rates.
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Pfizer Inc. (PFE) and Citigroup Inc. (C).
Yahoo Finance's Alexandra Semenova breaks down what to watch from big banks as they're set to release earnings this week.
Shares of Nvidia (NASDAQ: NVDA) were down 4.5% as of 1:15 p.m. ET on Monday, following another analyst weighing in with a warning for investors. This has sent Nvidia shares down 60% year to date. Nvidia stands to lose $400 million in quarterly revenue.
It may not be practical — at least for now.
A Cowen analyst says chip stocks are near all-time low valuations after their big drops this year. Several offer solid buying opportunities.
Shares of Ford Motor Co. were hit hard Monday by UBS analyst Patrick Hummel's recommendation that investors sell, as the auto industry is facing a worrisome U-turn from undersupply to oversupply.
Sports reporter Josh Schafer outlines how sports betting sites are reacting to California's vote on Prop 27, as well as how China's COVID-19 lockdowns are still impacting casino stocks.
(Bloomberg) — Everywhere you turn, the biggest players in the $23.7 trillion US Treasuries market are in retreat.Most Read from BloombergHere’s How Weird Things Are Getting in the Housing MarketScreening Procedure Fails to Prevent Colon Cancer Deaths in Large StudyThis Is What 7% Mortgages Will Do to the Housing MarketCathie Wood Warns of ‘Serious Losses’ in Automobile DebtPutin Threatens More Missile Attacks on Ukraine as Cities HitFrom Japanese pensions and life insurers to foreign government
Autos correspondent Pras Subramanian outlines Tesla's EV production figures from its factory in China, Rivian's recall, and analyst outlooks on Ford and General Motors amid inflation and supply chain concerns.
JPMorgan Chase & Co. CEO Jamie Dimon warns investors that stocks could slide much further as the Fed continues hiking interest rates.
It was yet another difficult day for automotive investors. This morning, share prices of Ford (NYSE: F) and General Motors (NYSE: GM) were sliding after a UBS analyst downgraded the automotive stocks. Nio (NYSE: NIO) investors weren't having much of a better morning either, as the Chinese automaker's stock was falling likely on news that fellow EV maker Rivian issued a significant recall of most of its vehicles.
Oil prices have bounced around quite a bit this year. Brent oil, the global-pricing benchmark, started 2022 below $80 a barrel before soaring into the $120s following Russia's invasion of Ukraine. With the prospect of higher oil prices, we asked some of our energy contributors what oil stocks they believe are best positioned to capitalize following OPEC's bold move.
Intel (NASDAQ: INTC) has been under tremendous pressure this year. Shares of the semiconductor company have tumbled about 50%. While Intel is facing its share of headwinds, I believe better days lie ahead for the tech giant and its big-time dividend.
Yahoo Finance's Brian Sozzi discusses a recent note from Morgan Stanley on IBM stock.